Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 88.83% | -62.37% | 87.69% | -1,213.90% | -27.12% |
| Total Depreciation and Amortization | 1.80% | 4.02% | -33.03% | 11.40% | -5.48% |
| Total Amortization of Deferred Charges | 28.41% | 50.00% | -51.52% | -- | -- |
| Total Other Non-Cash Items | -83.32% | 34.34% | -88.79% | 748.69% | -84.92% |
| Change in Net Operating Assets | 134.95% | 645.69% | 80.30% | -122.62% | 203.28% |
| Cash from Operations | 649.39% | 594.74% | -95.99% | -44.10% | -2.35% |
| Capital Expenditure | -373.68% | -11.76% | 78.75% | -70.21% | -105.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.26% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.14% | -8.97% | 51.00% | -1,371.76% | 53.80% |
| Cash from Investing | -7.28% | -9.05% | 52.02% | 81.25% | -1,156.11% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 0.67% | -11.23% | 11.62% | -22.20% | -1.97% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -389.83% | 137.26% | 8.74% | -17.66% | -0.54% |
| Foreign Exchange rate Adjustments | -103.30% | 254.26% | -51.04% | -51.64% | 148.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -94.54% | 140.61% | -45.26% | 50.61% | -1,005.05% |